CDT EQUITY INC. Net Fee Amt
CDT EQUITY INC. (CDT) had Net Fee Amt of $1.84 thousand as of 2026-09-08, per its S-1 filed 2026-09-08.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-09-08
- 2026-09-08: Net Fee Amt $1.84K.
- 2026-04-21: Net Fee Amt $2.66K.
| Period end | Net Fee Amt |
|---|---|
| 2026-09-08 | $1.84K S-1 · filed 2026-09-08 |
| 2026-04-21 | $2.66K S-3 · filed 2026-04-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |